Simone Brogi got his “Laurea” in Biological Sciences in 2005. During his Master training, he started the studies in the field of molecular modelling. He obtained the Ph.D. degree in Pharmaceutical Sciences in 2010. Actually, Dr Brogi is a research fellow at the Department of Biotechnology, Chemistry and Pharmacy at University of Siena, Italy. Dr Brogi is the head of Molecular Modeling Unit in the research group directed by Prof. Giuseppe Campiani. The scientific production of Dr Brogi consists of over 45 papers published on international peer-reviewed journals, one patent and one book chapter (full list of publications: https://www.researchgate.net/profile/Simone_Brogi). Specifically Dr Brogi has sound knowledge of various computational methodologies: Pharmacophore modeling, Virtual Screening, High throughput Docking (HTD), High throughput QM-Polarized Ligand Docking (HTQPLD), Molecular Docking, Homology Modeling, 3D-QSAR and 3D-QSSR models, Molecular Dynamics, QM/MM calculations, in silico prediction of ADME T Properties. Furthermore Dr Brogi possesses expertise in GPU calculation by means of CUDA technology applied to Molecular Dynamics software. Dr Brogi operates as reviewer for over 25 scientific journals. From November 2015 Dr Brogi is Associate Editor of “BMC Pharmacology & Toxicology”. From June 2016 Dr Brogi is a member of the Editorial Board of “Journal of Drug Research and Development”. From September 2016 Dr Brogi is Associate Editor of “Frontiers in Chemistry”. From October 2016 Dr Brogi is a member of the Editorial Board of “Pharmacology, Drug Development & Therapeutics (PDDT)”. From March 2017 Dr Brogi is a member of the Editorial Board of “NESSA Journal of Pharmacy and Pharmacology (NJPP)”. From May 2017 Dr Brogi is a member of the Editorial Board of “Journal of Addiction Therapy”. From July 2017 Dr Brogi is a member of the Editorial Board of “International Journal of Biopharmaceutical Sciences (IJBS)”.
Dr Brogi research activity has been mainly focused on computational approaches in drug discovery with particular attention to lead optimization in terms of pharmacokinetics properties and metabolic stability. The computational research of Dr Brogi includes the discovery and optimization of small-molecules as potential antalgic agents, antitumor compounds, and also with therapeutic potential for the treatment of neurodegenerative, cardiovascular, and parasitic diseases. These interests include target selection and the rational design of innovative drugs, the application and validation of novel computational strategies, and the study of important structure-function relationships. Lastly the research was focused on the development of computational tools for predicting off-targets.